Predicting Outcome in Cervix Carcinoma: a Prospective Study
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Cervical Cancer
- Sponsor
- Maastricht Radiation Oncology
- Enrollment
- 423
- Locations
- 2
- Primary Endpoint
- five-year overall survival rate
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
The main aim is to validate and improve the predictive model for survival and toxicity in patients with cervical cancer through multicentric prospective data collection. The data contain information on patient, tumor and treatment characteristics. For this study, additional health related QOL scores will be assessed using the EORTC Quality of Life Questionair-CX24 and C30. The long term aim, beyond this specific study, is to build a Decision Support System based on the predictive model validated in this study.
Investigators
Eligibility Criteria
Inclusion Criteria
- •histological or cytological proven cervical cancer
- •informed consent according to national rules
Exclusion Criteria
- •no histological or cytological proven cervical cancer
- •no informed consent according to national rules
Outcomes
Primary Outcomes
five-year overall survival rate
Time Frame: 5 years after treatment
assessment of the overall survival 5 years after treatment
Secondary Outcomes
- three-year distant disease free survival(3 years)
- three-year local disease free survival(3 years)
- five-year distant disease free survival(5 years)
- five-year local disease free survival(5 years)
- number of participants with early adverse events as a measure of safety and tolerability(2 months)
- number of participants with late adverse events as a measure of safety and tolerability(5 years)